Top

Strahlentherapie und Onkologie

Published in:

01-04-2017 | Original Article

Role of postoperative radiotherapy in the management of malignant pleural mesothelioma

A propensity score matching of the SEER database

Author: Omar Abdel-Rahman

Published in: Strahlentherapie und Onkologie | Issue 4/2017

Abstract

Introduction

This study assessed the prognostic impact of postoperative radiotherapy in patients with surgically resected malignant pleural mesothelioma (MPM).

Methods

MPM patients diagnosed between 2000 and 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. A propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TNM stage, and type of surgery).

Results

A total of 2166 patients were identified. The median age was 60 years (range 25–85 years), and 469 patients received postoperative radiotherapy. Both before and after propensity score matching, overall survival (P < 0.0001 and P = 0.012, respectively) was better in the postoperative radiotherapy group. When the overall survival was stratified by histology, postoperative radiotherapy did not improve the survival in sarcomatoid histology patients both before and after matching (P = 0.424 and P = 0.281, respectively). In multivariate analysis of the matched population, not receiving postoperative radiotherapy did not correlate with worse survival (hazard ratio: 1.175; P = 0.12). Factors associated with worse survival include sarcomatoid histology, nodal positivity, and age ≥70.

Conclusion

Evidence from this analysis is insufficient on its own to routinely recommend postoperative radiotherapy for surgically resected MPM. However, large-scale prospective clinical trials are warranted to further evaluate this intervention in nonsarcomatoid histology.

Available only for authorised users

Panou V, Vyberg M, Weinreich U, Meristoudis C, Falkmer U, Røe O (2015) The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. doi:10.1016/j.ctrv.2015.05.001 PubMed

Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T et al (2007) Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369(9564):844–849CrossRefPubMed

Blomberg C, Nilsson J, Holgersson G, Edlund P, Bergqvist M, Adwall L et al (2015) Randomized trials of systemic medically-treated malignant mesothelioma: A systematic review. Anticancer Res 35(5):2493–2501PubMed

Røe OD, Stella GM (2015) Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 24(135):115–131CrossRefPubMed

Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA (2015) Changing pattern in malignant mesothelioma survival. Transl Oncol 8(1):35–39CrossRefPubMedPubMedCentral

Davidson B (2015) Prognostic factors in malignant pleural mesothelioma. Hum Pathol 46(6):789–804CrossRefPubMed

Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366(9483):397–408CrossRefPubMed

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35(3):479–495CrossRefPubMed

Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Safi S et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 10:267CrossRefPubMedPubMedCentral

10.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644CrossRefPubMed

11.

Abdel-Rahman O, Kelany M (2015) Systemic therapy options for malignant pleural mesothelioma beyond first line therapy. Expert Rev Respir Med. doi:10.1586/17476348.2015.1083426

12.

Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99(2):472–480CrossRefPubMed

13.

Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353(15):1591–1603CrossRefPubMed

14.

Surveillance, Epidemiology and End Results Program. About the SEER Program. Available at: http://seer.cancer.gov/about. Accessed 25 June 2016

15.

Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41–55CrossRef

16.

Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39(1):33–38

17.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424CrossRefPubMedPubMedCentral

18.

Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L et al (2010) Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol 5(10):1649–1654CrossRefPubMed

19.

Chapman E, Berenstein EG, Dieguez M, Ortiz Z (2006) Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 3:CD003880

20.

Nagendran M, Pallis A, Patel K, Scarci M (2011) Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? Interact Cardiovasc Thorac Surg 13(1):66–69CrossRefPubMed

21.

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N et al (2016) Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol 17(8):1094-1104CrossRefPubMedPubMedCentral

22.

Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763–772CrossRefPubMedPubMedCentral

23.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A et al (2015) Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16(16):1651–1658CrossRefPubMed

24.

Rimner A, Simone CB 2nd, Zauderer MG, Cengel KA, Rusch VW (2016) Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? Lancet Oncol 17(2):e43–e44CrossRefPubMed

25.

Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA et al (2015) Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 196(1):23–32CrossRefPubMedPubMedCentral

26.

Taioli E, Wolf AS, Camacho-Rivera M, Kaufman A, Lee D‑S, Nicastri D et al (2015) Determinants of survival in malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLOS ONE 10(12):e0145039CrossRefPubMedPubMedCentral

27.

Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, Drigo A et al (2015) Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys 93(3):606–613CrossRefPubMed

Title: Role of postoperative radiotherapy in the management of malignant pleural mesothelioma
A propensity score matching of the SEER database
Author: Omar Abdel-Rahman
Publication date: 01-04-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 4/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-1092-7

At a glance: The STEP trials

Springer Medicine

Role of postoperative radiotherapy in the management of malignant pleural mesothelioma

A propensity score matching of the SEER database

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Brusterhaltende Therapie mit adjuvanter Radiotherapie des Mammakarzinoms besser als die Mastektomie?

Radiotherapy in desmoid tumors

Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters

Radiotherapy for aneurysmal bone cysts

Stereotaktische Radiochirurgie bei Metastasen im Hirnstamm

Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?